eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
07 Juin 2022 - 2:00PM
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical
company pioneering the development of selective translation
regulator inhibitors (STRIs) for the treatment of cancer, today
announced that the Company will present and host 1x1 meetings at
JMP Securities Life Sciences Conference.
The eFFECTOR Team is scheduled to hold a fireside chat on June
15th at 10:30 am ET and will host investor meeting at the
conference through June 16th.
A live webcast will be available on the "Events and
Presentation" page of the Investors section of the Company’s
website. A replay of the webcasts will be available for 30 days
following the event. For more information, please visit
investors.effector.com.
About eFFECTOR
TherapeuticseFFECTOR is a clinical-stage biopharmaceutical
company pioneering the development of a new class of oncology drugs
referred to as STRIs. eFFECTOR’s STRI product candidates target the
eIF4F complex and its activating kinase, mitogen-activated protein
kinase interacting kinase (MNK). The eIF4F complex is a central
node where two of the most frequently mutated signaling pathways in
cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the
translation of select mRNA into proteins that are frequent culprits
in key disease-driving processes. Each of eFFECTOR’s product
candidates is designed to act on a single protein that drives the
expression of a network of functionally related proteins, including
oncoproteins and immunosuppressive proteins in T cells, that
together control tumor growth, survival and immune evasion.
eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor
currently being evaluated in KICKSTART, a randomized, double-blind,
placebo-controlled Phase 2b trial of tomivosertib in combination
with pembrolizumab in patients with metastatic non-small cell lung
cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is
currently being evaluated in Phase 2a expansion cohorts in certain
biomarker-positive solid tumors, including ER+ breast cancer and
KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer
to develop inhibitors of a third target, eIF4E. In addition to the
company’s oncology focus, zotatifin is being evaluated as a
potential host-directed anti-viral therapy in patients with mild to
moderate COVID-19 in collaboration with the University of
California, San Francisco, under a $5 million grant sponsored by
the Defense Advanced Research Projects Agency.
Contacts:
Investors:Stephanie CarringtonWestwicke, an ICR
Company646-277-1282Stephanie.Carrington@westwicke.com
Media:Heidi Chokeir, Ph.D.Canale
Communications619-203-5391heidi.chokeir@canalecomm.com
eFFECTOR Therapeutics (NASDAQ:EFTR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
eFFECTOR Therapeutics (NASDAQ:EFTR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024